BHC Bausch Health Companies Inc.

18.34
-0.08  -0%
Previous Close 18.42
Open 18.56
52 Week Low 11.15
52 Week High 31.97
Market Cap $6,505,701,323
Shares 354,722,639
Float 311,493,941
Enterprise Value $26,604,915,555
Volume 3,237,005
Av. Daily Volume 5,657,676
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
EM-100
Allergic conjunctivitis
PDUFA
PDUFA
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
IDP-120
Acne
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
IDP-124
Atopic Dermatitis
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
XIPERE (Suprachoroidal CLS-TA)
Macular edema associated with non-infectious uveitis
NDA Filing
NDA Filing
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
Amiselimod S1P6 Modulator
Phase 2
Phase 2
Phase 2 trial to commence 2H 2020.
Rifaximin
Small intestinal bacterial overgrowth (SIBO)
Phase 2
Phase 2
Phase 2 trial planned.
Rifaximin
Crohn's disease
Phase 2/3
Phase 2/3
Phase 2/3 trial to commence 2Q 2021.
IDP-126
Acne
Phase 3
Phase 3
Phase 3 trial ongoing.
DUOBRII (halobetasol propionate and tazarotene)
Psoriasis
Approved
Approved
FDA approval announced April 25, 2019.
Rifaximin
Overt hepatic encephalopathy
Phase 2
Phase 2
Phase 2 data met primary endpoint - March 31, 2020.
IDP-123
Acne
Approved
Approved
FDA Approval announced December 19, 2019.
Loteprednol Gel 0.38%
Ocular Inflammation
Approved
Approved
FDA approval announced February 25, 2019.
IDP-122
Psoriasis
Approved
Approved
Tentative FDA Approval announced October 8, 2018. Final approval expected November 2018 pending the expiration of exclusivity for a related product.
IDP-121
Acne
Approved
Approved
FDA Approval announced August 24, 2018.
ULTRA - 7 days
Contact lens
Approved
Approved
Approval announced March 2, 2018.
Plenvu (NER1006)
Bowel cleansing
Approved
Approved
Approval announced May 7, 2018.
Latanoprostene bunod
Open angle glaucoma (OAG) or ocular hypertension (OHT)
Approved
Approved
Approval announced November 2, 2017.
LUMIFY (brimonidine tartrate ophthalmic solution 0.025%)
Eye Brightener
Approved
Approved
Approval announced December 22, 2017.
Brodalumab
Psoriasis
Approved
Approved
Approved February 15, 2017.

Latest News

  1. NESS ZIONA, Israel, June 29, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that it has entered into collaborative agreements with Perrigo Company plc ("Perrigo") (NYSE; TASE: PRGO), for the development, manufacturing and commercialization of three new, generic product candidates.

    Consistent with Sol-Gel's prior agreements with Perrigo, Perrigo will seek regulatory approval with the U.S. Food and Drug Administration ("FDA") for these generic product candidates. If approved by the FDA, Perrigo will lead the commercialization efforts for…

    NESS ZIONA, Israel, June 29, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that it has entered into collaborative agreements with Perrigo Company plc ("Perrigo") (NYSE; TASE: PRGO), for the development, manufacturing and commercialization of three new, generic product candidates.

    Consistent with Sol-Gel's prior agreements with Perrigo, Perrigo will seek regulatory approval with the U.S. Food and Drug Administration ("FDA") for these generic product candidates. If approved by the FDA, Perrigo will lead the commercialization efforts for the generic product candidates in the United States. Sol-Gel and Perrigo will share the development costs and any gross profits generated from potential sales of the generic product candidates.

    "Just a year ago, Sol-Gel entered into a seventh agreement with Perrigo to develop, manufacture and commercialize two generic formulations and we are thrilled to now expand the collaboration to cover these three, new product candidates," stated Dr. Alon Seri-Levy, Chief Executive Officer of Sol-Gel. "Our collaboration with Perrigo is generating meaningful revenue for Sol-Gel as we continue to focus on the submission and commercialization of our own branded product candidates Epsolay® and Twyneo®, which we expect to file NDAs for in the second quarter and second half of this year, respectively."

    Separately, Sol-Gel notes that Bausch Health Companies, Inc. (NYSE:BHC) filed a patent infringement action regarding Perrigo's Abbreviated New Drug Application ("ANDA") for a generic version of Bryhali® (halobetasol propionate) lotion, 0.01%, for the treatment of plaque psoriasis in adults.  The halobetasol propionate lotion, 0.01%, development is covered under a previous collaboration between Sol-Gel and Perrigo.

    About Sol-Gel Technologies

    Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for Twyneo, for the treatment of acne vulgaris, and Epsolay, for the treatment of papulopustular rosacea. The Company's pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, for the treatment of palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit www.sol-gel.com.

    Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the timing of the submission of an NDA for Epsolay and an NDA for Twyneo and the development of our generic product candidates in collaboration with Perrigo. These forward-looking statements include information about possible or assumed future results of our business, financial condition, results of operations, liquidity, plans and objectives. In some cases, you can identify forward-looking statements by terminology such as "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," "predict," "potential," or the negative of these terms or other similar expressions. Forward-looking statements are based on information we have when those statements are made or our management's current expectation and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to, risks relating to the effects of COVID-19 (coronavirus), the timing of a launch of a branded tapinarof product and the launch of a branded topical roflumilast in the U.S., risks related to the timing of the submission of an NDA for Epsolay and an NDA for Twyneo as well as the following factors: (i) the adequacy of our financial and other resources, particularly in light of our history of recurring losses and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives; (ii) our ability to complete the development of our product candidates; (iii) our ability to find suitable co-development partners; (iv) our ability to obtain and maintain regulatory approvals for our product candidates in our target markets and the possibility of adverse regulatory or legal actions relating to our product candidates even if regulatory approval is obtained; (v) our ability to commercialize our pharmaceutical product candidates; (vi) our ability to obtain and maintain adequate protection of our intellectual property; (vii) our ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost; (viii) our ability to establish adequate sales, marketing and distribution channels; (ix) acceptance of our product candidates by healthcare professionals and patients; (x) the possibility that we may face third-party claims of intellectual property infringement; (xi) the timing and results of clinical trials that we may conduct or that our competitors and others may conduct relating to our or their products; (xii) intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; (xiii) potential product liability claims; (xiv) potential adverse federal, state and local government regulation in the United States, Europe or Israel; and (xv) loss or retirement of key executives and research scientists. These and other important factors discussed in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission ("SEC") on March 24 , 2020 and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. Except as required by law, we undertake no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements.



    For further information, please contact:

    Sol-Gel Contact:

    Gilad Mamlok

    Chief Financial Officer

    +972-8-9313433

    Investor Contact:

    Lee M. Stern

    Solebury Trout

    646-378-2922

    Primary Logo

    View Full Article Hide Full Article
  2. ARAZLO (tazarotene) Lotion, 0.045% is Indicated for the Topical Treatment of Acne Vulgaris in Patients Nine Years of Age and Older

    LAVAL, QC, June 23, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses in the world, today announced that ARAZLO (tazarotene) Lotion, 0.045%, is available commercially to health care professionals in the United States this week. Approved by the U.S. Food and Drug Administration (FDA) in December 2019, ARAZLO is the first tazarotene acne treatment available in lotion formulation.

    "Retinoids like tazarotene are highly effective in treating acne and considered a cornerstone of acne treatment…

    ARAZLO (tazarotene) Lotion, 0.045% is Indicated for the Topical Treatment of Acne Vulgaris in Patients Nine Years of Age and Older

    LAVAL, QC, June 23, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses in the world, today announced that ARAZLO (tazarotene) Lotion, 0.045%, is available commercially to health care professionals in the United States this week. Approved by the U.S. Food and Drug Administration (FDA) in December 2019, ARAZLO is the first tazarotene acne treatment available in lotion formulation.

    "Retinoids like tazarotene are highly effective in treating acne and considered a cornerstone of acne treatment, but often are perceived to be associated with skin irritation.1 Clinical studies have demonstrated that ARAZLO's proprietary formulation provides the proven efficacy of a retinoid in a lotion that is more tolerable to patients than a higher concentration tazarotene," said Bill Humphries, president, Ortho Dermatologics. "Ortho Dermatologics remains committed to bringing forward new treatment options like ARAZLO to help the millions of Americans who suffer from acne."

    In a Phase 2, head-to-head study, ARAZLO and Tazorac (tazarotene) Cream 0.1% showed similar treatment success rates and similar reductions in both inflammatory and non-inflammatory lesions over 12 weeks and ARAZLO was associated with about half the number of adverse events and fewer treatment-related adverse events.1

    "The novel lotion formulation of ARAZLO has been shown to be generally well-tolerated, allowing more patients with multiple types of acne to take advantage of its efficacy1," said Emil Tanghetti, M.D., lead ARAZLO study investigator and founder of the Center for Dermatology and Laser Surgery, Sacramento, Calif. "I am excited to offer ARAZLO to my patients and anticipate they will be pleased with their results."

    ARAZLO is priced comparable to many other branded acne products indicated to treat moderate-to-severe acne vulgaris. For most eligible patients whose commercial insurance covers the product, they should have no co-pay (or $0 co-pay) when utilizing the ARAZLO coupon at participating pharmacies. Most other eligible, commercially insured patients will have a co-pay of as little as $65 through our access program.

    ARAZLO Comprehensive Clinical Data

    The FDA approval for ARAZLO was based on data from two Phase 3 multicenter, randomized, double- blind, vehicle-controlled clinical trials in 1,614 patients with moderate to severe acne. In both Phase 3 studies, all primary efficacy endpoints were met with statistical significance (p<.001). ARAZLO was also shown to be generally well-tolerated in the clinical study population.2

    In a Phase 2, head-to-head study, ARAZLO and Tazorac (tazarotene) Cream 0.1% showed similar treatment success rates and similar reductions in both inflammatory and non-inflammatory lesions over 12 weeks.2 While there were no significant differences in patient satisfaction or quality of life and both were well-tolerated, Tazorac was associated with nearly double the number of treatment-related adverse events (5.6 percent with Tazorac versus 2.9 percent with ARAZLO), the study reported.2

    About Acne Vulgaris

    Acne is the most common skin problem in the United States, which occurs when hair follicles become plugged with oil and skin cells, often causing whiteheads, blackheads or pimples to appear on the face, forehead, chest, upper back and shoulders.3 Up to 50 million Americans have acne.4 Depending on its severity, acne can cause emotional distress and scar the skin.3

    Important Safety Information for ARAZLOTM (tazarotene) Lotion, 0.045%

    What is ARAZLO?

    ARAZLO™ (tazarotene) Lotion, 0.045% is a prescription medicine used on the skin (topical) to treat people 9 years of age and older with acne, which can include blackheads, whiteheads, and other pimples.

    It is not known if ARAZLO is safe and effective in children under 9 years of age.

    Important Safety Information

    ARAZLO is for use on skin only. Do not use ARAZLO in your eyes, mouth, the corners of your nose, or vagina.

    What is the most important information I should know about ARAZLO?

    • ARAZLO may cause birth defects if used during pregnancy.
    • You must not be pregnant when you start using ARAZLO or become pregnant during treatment.
    • Use effective birth control during treatment.
    • Stop using ARAZLO and tell your healthcare provider right away if you become pregnant during treatment.

    Before using ARAZLO, tell your healthcare provider about all your medical conditions, including if you:

    • have eczema or any other skin problems.
    • are breastfeeding or plan to breastfeed. If you use ARAZLO while breastfeeding, use it for the shortest time needed. Do not apply ARAZLO directly to the nipple and surrounding area to avoid exposing your child to the medicine.

    Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain medicines can make your skin more sensitive to sunlight; ask your healthcare provider for a list of medicines if you are not sure.

    Especially tell your healthcare provider about other products you use on your skin (such as benzoyl peroxide), including moisturizers, creams, lotions, or products that can dry out your skin.

    What should I avoid while using ARAZLO?

    • You should avoid sunlamps, tanning beds, and ultraviolet light during treatment with ARAZLO.
    • Minimize exposure to sunlight; you could get severe sunburn.

    If you have to be in the sunlight or are sensitive to sunlight, use a sunscreen with an SPF (sun protection factor) of 15 or more and wear protective clothing and a wide-brimmed hat to cover the treated areas.

    • Avoid using ARAZLO on skin with eczema or sunburned skin because it may cause severe irritation.

    ARAZLO may cause side effects, including:

    Skin irritation. ARAZLO may cause irritation including skin dryness, pain, redness, excessive flaking or peeling. If you develop these symptoms, your healthcare provider may tell you to use a moisturizer, adjust the dosing, or completely stop treatment with ARAZLO.

    These are not all the possible side effects of ARAZLO. Call your doctor for medical advice about side effects. You may report side effects to Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA- 1088.

    Please click here for full Prescribing Information, including Patient Information.

    About Ortho Dermatologics

    Ortho Dermatologics is one of the largest prescription and aesthetic dermatology businesses dedicated to helping patients in the treatment of a range of therapeutic areas, including psoriasis, actinic keratosis, acne, atopic dermatitis and other dermatoses. The Ortho Dermatologics portfolio also includes several leading medical device systems for aesthetic applications, such as skin tightening and resurfacing, laser hair removal and preventative therapeutic skin care treatments. More information can be found at www.ortho-dermatologics.com.

    About Bausch Health

    Bausch Health Companies Inc. (TSX:BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.

    Forward-looking Statements

    This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

    References

    1. Tanghetti EA, Kircik LH, Green LJ, et. Al. A Phase 2 multicenter, double-blind, randomized, vehicle- controlled clinical study to compare the safety and efficacy of a novel tazarotene 0.045% lotion and tazarotene 0.1% cream in the treatment of moderate-to-severe acne vulgaris. J Drugs Dermatol. 2019;18(6):542-548.
    2. ARAZLO Lotion [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC.
    3. Mayo Clinic. (2020). Acne. Retrieved from https://www.mayoclinic.org/diseases-conditions/acne/symptoms-causes/syc-20368047. Accessed Apr. 30, 2020.
    4. American Academy of Dermatology. (2019). Skin conditions by the numbers. Retrieved from https://www.aad.org/media/stats/conditions/skin-conditions-by-the-numbers. Accessed June 4, 2020.

    ARAZLO is a trademark of Ortho Dermatologics' affiliated entities.

    Any other product/brand names are trademarks of the respective owners.

    © 2020 Ortho Dermatologics' affiliated entities.

    ARZ.0078.USA.20

    Investor Contact:

    Media Contact:

    Arthur Shannon

    Lainie Keller

    (514) 856-3855

    (908) 927-1198

    (877) 281-6642 (toll free)

     

    Bausch Health logo (PRNewsfoto/Bausch Health Companies Inc.)

     

    (PRNewsfoto/Valeant Pharmaceuticals Interna)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ortho-dermatologics-launches-arazlo-tazarotene-lotion-0-045-in-the-united-states-301081310.html

    SOURCE Bausch Health Companies Inc.

    View Full Article Hide Full Article
  3. BRIDGEWATER, N.J., June 17, 2020 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health"), today announced that BAUSCH + LOMB ULTRA® monthly silicone hydrogel contact lenses have received approval from the National Medical Products Administration in China. BAUSCH + LOMB ULTRA® contact lenses feature MOISTURESEAL® technology, which maintains 95% of lens moisture for a full 16 hours.1

    "We are excited to offer BAUSCH + LOMB ULTRA® as a new option for eye care practitioners and their patients in China in the near future. BAUSCH + LOMB ULTRA® offers all-day comfort and consistent clear vision. It is a testimonial to our commitment of helping people in China to see better, live…

    BRIDGEWATER, N.J., June 17, 2020 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health"), today announced that BAUSCH + LOMB ULTRA® monthly silicone hydrogel contact lenses have received approval from the National Medical Products Administration in China. BAUSCH + LOMB ULTRA® contact lenses feature MOISTURESEAL® technology, which maintains 95% of lens moisture for a full 16 hours.1

    "We are excited to offer BAUSCH + LOMB ULTRA® as a new option for eye care practitioners and their patients in China in the near future. BAUSCH + LOMB ULTRA® offers all-day comfort and consistent clear vision. It is a testimonial to our commitment of helping people in China to see better, live better," said Thomas J. Appio, President, Bausch + Lomb/International.

    About Bausch + Lomb

    Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., is solely focused on helping people see. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries. For more information, visit www.bausch.com.

    About Bausch Health

    Bausch Health Companies Inc. (TSX:BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.

    Forward-looking Statements

    This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

    1.  Data on file. Bausch & Lomb Incorporated. Rochester, NY.

    BAUSCH + LOMB ULTRA and MoistureSeal are trademarks of Bausch & Lomb Incorporated or its affiliates.

    © 2020 Bausch & Lomb Incorporated or its affiliates.

    UMT.0138.USA.20

    Investor Contact:                                         

    Media Contact:

    Arthur Shannon                                               

    Lainie Keller

                    

    (514) 856-3855                                                 

    (908) 927-1198

    (877) 281-6642 (toll free)                 



    Bausch Health logo (PRNewsfoto/Bausch Health Companies Inc.)

    (PRNewsfoto/Valeant Pharmaceuticals Interna)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/bausch--lomb-ultra-silicone-hydrogel-contact-lenses-receive-approval-in-china-301079036.html

    SOURCE Bausch Health Companies Inc.

    View Full Article Hide Full Article
  4. LAVAL, Quebec, June 16, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) today announced that Paul S. Herendeen, executive vice president and chief financial officer, Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, and William Woodfield, vice president and treasurer, are scheduled to participate at the virtual Goldman Sachs Leveraged Finance Conference on June 25, 2020, at 11:25 a.m. EDT.

    A live webcast and audio archive of the events will be available on the Investor Relations page of the Bausch Health Companies Inc. web site at: http://ir.bauschhealth.com/events-and-presentations/2020.

    About Bausch Health
    Bausch Health Companies Inc. (TSX:BHC) is a global company whose mission is to improve…

    LAVAL, Quebec, June 16, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) today announced that Paul S. Herendeen, executive vice president and chief financial officer, Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, and William Woodfield, vice president and treasurer, are scheduled to participate at the virtual Goldman Sachs Leveraged Finance Conference on June 25, 2020, at 11:25 a.m. EDT.

    A live webcast and audio archive of the events will be available on the Investor Relations page of the Bausch Health Companies Inc. web site at: http://ir.bauschhealth.com/events-and-presentations/2020.

    About Bausch Health

    Bausch Health Companies Inc. (TSX:BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.

    Investor Contact:

    Media Contact:

    Arthur Shannon

    Lainie Keller

    (514) 856-3855

    (908) 927-1198

    (877) 281-6642 (toll free)



     

    Bausch Health logo (PRNewsfoto/Bausch Health Companies Inc.)

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/bausch-health-to-participate-at-goldman-sachs-annual-leveraged-finance-conference-301075178.html

    SOURCE Bausch Health Companies Inc.

    View Full Article Hide Full Article
  5. LAVAL, QC, June 15, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) diseases, today announced the recipients of the inaugural Salix Gastrointestinal Health Scholars Program. Ten outstanding students living with GI disease who are pursuing their higher education goals will each receive a $10,000 scholarship award.

    "At Salix, we understand the complexities of managing GI disease. We created the Salix Gastrointestinal Health Scholars Program to recognize students who are working diligently to achieve their higher educational goals while…

    LAVAL, QC, June 15, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) diseases, today announced the recipients of the inaugural Salix Gastrointestinal Health Scholars Program. Ten outstanding students living with GI disease who are pursuing their higher education goals will each receive a $10,000 scholarship award.

    "At Salix, we understand the complexities of managing GI disease. We created the Salix Gastrointestinal Health Scholars Program to recognize students who are working diligently to achieve their higher educational goals while living with the challenges of a GI disease," said Robert Spurr, president, Salix. "We are inspired by the incredible resiliency and determination each of our winners has displayed in pursuit of their education."

    The 2020 honorees were selected from more than 100 applications, based in part on essays sharing their experiences pursuing their education while living with a gastrointestinal condition. In their essays, applicants also shared the role their gastroenterologist, primary care physician or allied health care professional played in helping them reach their goals. The applications were reviewed by an independent panel of judges.

    The Salix Gastrointestinal Health Scholars Program recognizes students across a wide range of educational pursuits, with scholarship awards in four categories, including the Undergraduate Scholar Awards for those pursuing undergraduate degrees; the Graduate Scholar Awards for those pursuing graduate degrees; the Working Parent's Scholar Award for working parents pursuing undergraduate, vocational/technical or graduate degrees; and the Single Parent's Scholar Award for single parents pursuing undergraduate, vocational/technical or graduate degrees.

    The 2020 Salix Gastrointestinal Health Scholars Program recipients are:

    • Undergraduate Scholar Awards 
      • Jenny Peters, Smyrna, Tenn. – The University of Alabama
      • Julia Piligian, South Hadley, Mass.University of Massachusetts Lowell
      • Kyla Sorensen, Seattle, Wash.Western Washington University
      • Ryan Soto, Cibolo, TexasTrinity University

         
    • Graduate Scholar Awards 
      • Jakob Ozer, Needham, Mass.Boston University
      • Jocelyn Perez, Revere, Mass.Columbia University
      • Natacha Richemond, Atlanta, Ga. – The George Washington University
      • Samin Panahi, Bethesda, Md.University of Maryland

         
    • Working Parent's Scholar Award 
      • Audriana Duvall, Baltimore, Md. – The University of Baltimore

         
    • Single Parent's Scholar Award 
      • LaQuenta Baker, Helena, Ark.Phillips Community College of the University of Arkansas

    To learn more about the Salix Gastrointestinal Health Scholars Program, visit www.Salix.com/Scholarship. The 2021 Salix Gastrointestinal Health Scholars Program will begin accepting applications in November 2020.

    About the Salix Gastrointestinal Health Scholars Program

    The Salix Gastrointestinal Health Scholars Program, which is funded through the Bausch Foundation, is aimed at providing financial support to outstanding students who have not allowed GI disease to stand in the way of their academic achievements.

    About the Bausch Foundation

    The Bausch Foundation was established in 2017 to improve the lives of patients globally by providing access to safe, effective medicines and by financially supporting health care education and causes around the world. Since its inception, the Bausch Foundation has contributed millions of dollars' worth of financial and product donations to global charitable health organizations.

    About Salix

    Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For 30 years, Salix has licensed, developed, and marketed innovative products to improve patients' lives and arm healthcare providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists and primary care. Salix is headquartered in Bridgewater, N.J.

    About Bausch Health

    Bausch Health Companies Inc. (TSX:BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.

    Forward-looking Statements

    This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in the Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

    SAL.0098.USA.20

    ©2020 Salix Pharmaceuticals or its affiliates.

     

    Investor Contact:   













    Media Contact:

    Arthur Shannon   













    Lainie Keller

       













    (514) 856-3855    













    908) 927-1198

    (877) 281-6642 (toll free)





























    Karen Paff















     















    (908) 927-1190

     

    Bausch Health logo (PRNewsfoto/Bausch Health Companies Inc.)

     

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/salix-announces-inaugural-salix-gastrointestinal-health-scholars-program-recipients-301076570.html

    SOURCE Bausch Health Companies Inc.

    View Full Article Hide Full Article
View All Bausch Health Companies Inc. News